ArticleMolecular cancer2025

IFITM3-MET interaction drives osimertinib resistance through AKT pathway activation in EGFR-mutant non-small cell lung cancer.

Ritsu Ibusuki et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.